Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Aspergillosis | 5 | 2021 | 264 | 1.96 | Why? |
| Azoles | 3 | 2018 | 185 | 1.82 | Why? |
| Hepatitis C | 7 | 2019 | 1514 | 1.74 | Why? |
| Aspergillus fumigatus | 4 | 2019 | 239 | 1.30 | Why? |
| Cytochrome P-450 Enzyme System | 3 | 2019 | 144 | 1.30 | Why? |
| Fungal Proteins | 3 | 2019 | 133 | 1.30 | Why? |
| Invasive Pulmonary Aspergillosis | 7 | 2021 | 634 | 1.16 | Why? |
| Drug Resistance, Fungal | 5 | 2019 | 191 | 1.15 | Why? |
| Antifungal Agents | 6 | 2020 | 1828 | 1.11 | Why? |
| Heterocyclic Compounds, 3-Ring | 5 | 2019 | 275 | 1.05 | Why? |
| HIV Integrase Inhibitors | 3 | 2018 | 173 | 0.93 | Why? |
| HIV Seronegativity | 2 | 2018 | 112 | 0.91 | Why? |
| Homosexuality, Male | 4 | 2018 | 1158 | 0.88 | Why? |
| HIV Infections | 16 | 2022 | 11620 | 0.82 | Why? |
| HIV | 6 | 2022 | 1116 | 0.81 | Why? |
| Quinoxalines | 2 | 2019 | 95 | 0.76 | Why? |
| Benzofurans | 2 | 2019 | 91 | 0.74 | Why? |
| Lamivudine | 1 | 2019 | 210 | 0.71 | Why? |
| Hepatitis C Antigens | 1 | 2017 | 18 | 0.71 | Why? |
| Sexually Transmitted Diseases, Viral | 1 | 2018 | 115 | 0.64 | Why? |
| Netherlands | 9 | 2019 | 3533 | 0.56 | Why? |
| Shigella flexneri | 1 | 2014 | 14 | 0.56 | Why? |
| Dysentery, Bacillary | 1 | 2014 | 38 | 0.54 | Why? |
| Imidazoles | 2 | 2019 | 631 | 0.53 | Why? |
| CD4 Lymphocyte Count | 3 | 2019 | 1517 | 0.52 | Why? |
| Sexual and Gender Minorities | 3 | 2018 | 1019 | 0.47 | Why? |
| Oxazines | 5 | 2019 | 279 | 0.45 | Why? |
| Disease Eradication | 1 | 2018 | 581 | 0.45 | Why? |
| Piperazines | 5 | 2019 | 445 | 0.40 | Why? |
| Belgium | 4 | 2019 | 2064 | 0.37 | Why? |
| Hematologic Neoplasms | 2 | 2019 | 2105 | 0.36 | Why? |
| Anti-HIV Agents | 3 | 2017 | 2209 | 0.36 | Why? |
| Aspergillus | 3 | 2021 | 347 | 0.35 | Why? |
| Pyridones | 5 | 2019 | 738 | 0.34 | Why? |
| Drug Resistance, Viral | 3 | 2018 | 1083 | 0.33 | Why? |
| Hepacivirus | 4 | 2019 | 1509 | 0.30 | Why? |
| Pulmonary Aspergillosis | 2 | 2021 | 408 | 0.29 | Why? |
| Drug Resistance, Bacterial | 1 | 2014 | 1414 | 0.27 | Why? |
| Treatment Failure | 4 | 2019 | 2106 | 0.26 | Why? |
| HIV-1 | 5 | 2019 | 3365 | 0.26 | Why? |
| Influenza, Human | 4 | 2020 | 10779 | 0.24 | Why? |
| Microbial Sensitivity Tests | 4 | 2019 | 2886 | 0.23 | Why? |
| Acute Disease | 3 | 2019 | 6029 | 0.22 | Why? |
| Cytokines | 2 | 2021 | 15010 | 0.22 | Why? |
| Catheters, Indwelling | 1 | 2021 | 84 | 0.21 | Why? |
| Sustained Virologic Response | 2 | 2019 | 378 | 0.20 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.20 | Why? |
| Dideoxynucleosides | 1 | 2019 | 92 | 0.20 | Why? |
| Viral Load | 7 | 2019 | 15850 | 0.20 | Why? |
| Anti-Retroviral Agents | 2 | 2019 | 1099 | 0.19 | Why? |
| Cyclopropanes | 2 | 2019 | 332 | 0.19 | Why? |
| Transition Temperature | 1 | 2017 | 11 | 0.18 | Why? |
| Azithromycin | 1 | 2014 | 3943 | 0.18 | Why? |
| Antiviral Agents | 4 | 2019 | 41703 | 0.18 | Why? |
| Chromatography, Affinity | 1 | 2020 | 310 | 0.18 | Why? |
| Toxoplasmosis, Cerebral | 1 | 2017 | 12 | 0.18 | Why? |
| Carbamates | 2 | 2019 | 485 | 0.18 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.17 | Why? |
| Voriconazole | 1 | 2019 | 206 | 0.17 | Why? |
| Unsafe Sex | 1 | 2018 | 139 | 0.17 | Why? |
| Coinfection | 4 | 2018 | 6820 | 0.17 | Why? |
| Invasive Fungal Infections | 2 | 2019 | 274 | 0.17 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 1 | 2017 | 66 | 0.16 | Why? |
| Rilpivirine | 1 | 2017 | 65 | 0.16 | Why? |
| Bronchoalveolar Lavage Fluid | 3 | 2021 | 2309 | 0.16 | Why? |
| HIV Seropositivity | 1 | 2018 | 320 | 0.16 | Why? |
| Emtricitabine | 1 | 2017 | 202 | 0.15 | Why? |
| Deoxycholic Acid | 1 | 2014 | 17 | 0.15 | Why? |
| Mannans | 3 | 2021 | 218 | 0.14 | Why? |
| Mutation | 4 | 2019 | 12376 | 0.14 | Why? |
| Adenine | 1 | 2017 | 463 | 0.13 | Why? |
| Bronchoalveolar Lavage | 1 | 2017 | 603 | 0.13 | Why? |
| Harm Reduction | 1 | 2018 | 392 | 0.13 | Why? |
| Chemoprevention | 1 | 2018 | 585 | 0.13 | Why? |
| Substance Abuse, Intravenous | 1 | 2018 | 411 | 0.13 | Why? |
| RNA, Viral | 3 | 2019 | 32276 | 0.13 | Why? |
| Middle Aged | 20 | 2021 | 270681 | 0.13 | Why? |
| Tenofovir | 1 | 2017 | 449 | 0.13 | Why? |
| Hematologic Diseases | 1 | 2020 | 614 | 0.13 | Why? |
| Amphotericin B | 1 | 2014 | 256 | 0.13 | Why? |
| Humans | 38 | 2022 | 930598 | 0.13 | Why? |
| Male | 21 | 2021 | 367725 | 0.12 | Why? |
| Sulfonamides | 2 | 2019 | 1294 | 0.12 | Why? |
| Drug Therapy, Combination | 4 | 2019 | 7268 | 0.12 | Why? |
| Mycoses | 1 | 2019 | 589 | 0.12 | Why? |
| Hematology | 1 | 2019 | 649 | 0.12 | Why? |
| Influenza B virus | 1 | 2018 | 815 | 0.12 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 952 | 0.12 | Why? |
| Anti-Bacterial Agents | 1 | 2014 | 10083 | 0.11 | Why? |
| Staphylococcal Infections | 1 | 2021 | 1099 | 0.11 | Why? |
| Kaplan-Meier Estimate | 1 | 2021 | 4260 | 0.11 | Why? |
| Viremia | 1 | 2019 | 1020 | 0.11 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.11 | Why? |
| Administration, Oral | 1 | 2019 | 2340 | 0.11 | Why? |
| Amino Acid Substitution | 1 | 2018 | 1706 | 0.11 | Why? |
| Incidence | 5 | 2019 | 25622 | 0.11 | Why? |
| Sexually Transmitted Diseases | 1 | 2019 | 694 | 0.11 | Why? |
| Amides | 2 | 2019 | 1864 | 0.10 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.10 | Why? |
| Candidiasis | 1 | 2014 | 334 | 0.10 | Why? |
| Ribavirin | 1 | 2017 | 1182 | 0.10 | Why? |
| Galactose | 2 | 2020 | 201 | 0.10 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.10 | Why? |
| Encephalitis | 1 | 2017 | 797 | 0.10 | Why? |
| Prospective Studies | 3 | 2019 | 43301 | 0.10 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2017 | 1439 | 0.10 | Why? |
| Sexual Behavior | 1 | 2018 | 1322 | 0.10 | Why? |
| Intensive Care Units | 6 | 2021 | 29594 | 0.09 | Why? |
| Hepatitis C, Chronic | 1 | 2018 | 973 | 0.09 | Why? |
| Feasibility Studies | 1 | 2018 | 3467 | 0.09 | Why? |
| Maintenance Chemotherapy | 2 | 2018 | 133 | 0.09 | Why? |
| Immunization, Passive | 2 | 2021 | 10067 | 0.09 | Why? |
| Adult | 13 | 2019 | 244371 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.09 | Why? |
| Blood Donors | 1 | 2021 | 2956 | 0.08 | Why? |
| Genotype | 1 | 2019 | 4697 | 0.08 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2014 | 861 | 0.08 | Why? |
| Influenza A virus | 1 | 2018 | 2234 | 0.08 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.08 | Why? |
| Academic Medical Centers | 1 | 2018 | 3088 | 0.08 | Why? |
| Female | 15 | 2021 | 380317 | 0.06 | Why? |
| Venous Thrombosis | 1 | 2019 | 2739 | 0.06 | Why? |
| Sensitivity and Specificity | 3 | 2020 | 22971 | 0.06 | Why? |
| Transplant Recipients | 1 | 2019 | 4982 | 0.06 | Why? |
| Immunocompromised Host | 1 | 2019 | 5150 | 0.06 | Why? |
| Virus Replication | 2 | 2021 | 14331 | 0.06 | Why? |
| Candida | 2 | 2018 | 425 | 0.06 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.06 | Why? |
| Coagulase | 1 | 2021 | 44 | 0.06 | Why? |
| Antibodies, Monoclonal | 1 | 2021 | 8041 | 0.06 | Why? |
| Models, Biological | 1 | 2018 | 4907 | 0.05 | Why? |
| Aged | 8 | 2021 | 215776 | 0.05 | Why? |
| Prevalence | 2 | 2019 | 25773 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.05 | Why? |
| Blood Culture | 1 | 2021 | 308 | 0.05 | Why? |
| HIV Integrase | 1 | 2018 | 67 | 0.05 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 11367 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.04 | Why? |
| Retrospective Studies | 8 | 2020 | 105322 | 0.04 | Why? |
| APACHE | 1 | 2018 | 682 | 0.04 | Why? |
| Weight Loss | 1 | 2021 | 826 | 0.04 | Why? |
| Time Factors | 1 | 2019 | 31397 | 0.04 | Why? |
| Luminescent Measurements | 1 | 2020 | 924 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2018 | 10697 | 0.03 | Why? |
| Respiratory Tract Infections | 1 | 2014 | 6817 | 0.03 | Why? |
| Cricetinae | 1 | 2021 | 3344 | 0.03 | Why? |
| Mutation, Missense | 1 | 2018 | 863 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Continuity of Patient Care | 1 | 2022 | 1574 | 0.03 | Why? |
| High-Throughput Screening Assays | 1 | 2020 | 1783 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Drug Interactions | 1 | 2017 | 1653 | 0.03 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2018 | 2830 | 0.02 | Why? |
| Risk Factors | 1 | 2018 | 71621 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.02 | Why? |
| Administration, Inhalation | 1 | 2014 | 1647 | 0.02 | Why? |
| Child | 1 | 2017 | 70012 | 0.02 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.02 | Why? |
| Neutralization Tests | 1 | 2020 | 6698 | 0.02 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.02 | Why? |
| Survival Analysis | 1 | 2019 | 7592 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2017 | 2585 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.02 | Why? |
| Drug Combinations | 1 | 2014 | 3852 | 0.02 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.02 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2019 | 6740 | 0.02 | Why? |
| Disease Models, Animal | 1 | 2021 | 10998 | 0.02 | Why? |
| Critical Illness | 2 | 2018 | 17281 | 0.02 | Why? |
| Ritonavir | 1 | 2017 | 4212 | 0.01 | Why? |
| Mortality | 1 | 2019 | 7132 | 0.01 | Why? |
| Hospitals | 1 | 2022 | 11793 | 0.01 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Patient Admission | 1 | 2018 | 5250 | 0.01 | Why? |
| Alanine | 1 | 2017 | 5687 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.01 | Why? |
| Prognosis | 1 | 2019 | 32490 | 0.01 | Why? |
| Critical Care | 1 | 2018 | 14081 | 0.01 | Why? |
| Risk Assessment | 1 | 2019 | 25439 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2022 | 29620 | 0.01 | Why? |
| Animals | 1 | 2021 | 78931 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2014 | 22116 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2017 | 88759 | 0.01 | Why? |
| Young Adult | 1 | 2017 | 93724 | 0.00 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.00 | Why? |
Rijnders's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(192)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(130)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_